News for Unicycive Therapeutics, Inc. (UNCY)

LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ( UNCY), a clinical-stage biotechnology company developing therapies for pa

**media[545453]**

Significant Transaction in Unicycive Therapeutics Inc. On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction b

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a significant transaction involving Unicycive Therapeutics Inc (UNCY). The firm adde

LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ( UNCY), a clinical-stage biotechnology company developing therapies for pat

**media[472592]**

LOS ALTOS, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ( UNCY), a clinical-stage biotechnology company developing therapies for pat

**media[464691]**

– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and...

LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Unicycive shares steady on positive Phase 1 study results

UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day...

LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

California-based biopharmaceutical company Spruce Biosciences, Inc. (SPRB) is down over 77% in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Benchmark Company is pleased to announce its 12th Annual Discovery One-on-One Investor Conference to be...

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%